| A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Participants With Sickle Cell Disease (SCD). (NCT04912869) | Hoffmann-La Roche | 2022-03-26 |
| Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis (NCT05168384) | Abu Dhabi Stem Cells Center | 2022-03-26 |
| Assessment on Effects of Tongjiang Granule in Treating Nonerosive Reflux Disease Overlapping Epigastric Pain Syndrome (NCT05312463) | Xiyuan Hospital of China Academy of Chinese Medical Sciences | 2022-03-26 |
| Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia (NCT05601466) | Institute of Hematology & Blood Diseases Hospital, China | 2022-03-26 |
| Safety, Tolerability, PK, PD and Preliminary Efficacy of ONO-4685 (NCT05332704) | Ono Pharmaceutical Co., Ltd. | 2022-03-25 |
| A Study on the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of CAN106 in Subjects With PNH (NCT05539248) | CARE Pharma Shanghai Ltd. | 2022-03-25 |
| A Study in Patients With Advanced Cancers (NCT05320588) | BiOneCure Therapeutics Inc. | 2022-03-25 |
| A Study of LC542019 in Healthy Subjects and Subjects With T2DM (NCT06333977) | LG Chem | 2022-03-25 |
| DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr (NCT04106115) | University College, London | 2022-03-25 |
| Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI (NCT04332588) | University of Alabama at Birmingham | 2022-03-25 |
| A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors (NCT05355753) | C4 Therapeutics, Inc. | 2022-03-25 |
| Acute Effects of Cannabigerol (NCT05257044) | Washington State University | 2022-03-24 |
| A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma (NCT06144385) | Shanghai Ming Ju Biotechnology Co., Ltd. | 2022-03-24 |
| Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas (NCT04933617) | National Cancer Institute (NCI) | 2022-03-24 |
| PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) (NCT05259397) | Pfizer | 2022-03-24 |
| Sativex® and Gentamicin for Optimized Pharmagological Treatment in Older Patients (CanPan) (NCT05503147) | Ove Andersen | 2022-03-24 |
| Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants (NCT05260437) | GlaxoSmithKline | 2022-03-24 |
| Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients (NCT05251727) | Veloxis Pharmaceuticals | 2022-03-24 |
| A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects (NCT05277350) | SNIPR Biome Aps. | 2022-03-24 |
| A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan (NCT05286229) | AbbVie | 2022-03-24 |
| A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma (NCT05193604) | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 2022-03-24 |
| RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC (NCT05220748) | Rakuten Medical, Inc. | 2022-03-24 |
| Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors (NCT05357898) | SQZ Biotechnologies | 2022-03-24 |
| A Safety and Efficacy Study of Corneal Injection for Endothelial Dysfunction Using Human Corneal Endothelial Cell Therapy in Subjects With Corneal Edema Secondary to Endothelial Dysfunction (NCT05309135) | Aurion Biotech | 2022-03-24 |
| A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 Diabetes (NCT04992312) | Eli Lilly and Company | 2022-03-24 |
| The Safety and Efficacy of MoodElite T-4003-1 on Improving Mood in a Healthy Adult Population With Mild to Moderate Depressive Symptoms Not Eligible for Therapeutic Intervention (NCT05318456) | Chenland Nutritionals Inc. | 2022-03-24 |
| Pharmacokinetics and Bioavailability of Curcumin UP 30 Capsules in Healthy Adult Subjects (NCT05334043) | The Affiliated Hospital of Qingdao University | 2022-03-23 |
| a Safety and Tolerability Study of EP-9001A in Healthy Volunteers (NCT05278611) | Chengdu Easton Biopharmaceuticals Co,Ltd | 2022-03-23 |
| A Phase I Study of IBI325 in Patients With Advanced Solid Tumor (NCT05246995) | Shandong Cancer Hospital and Institute | 2022-03-23 |
| A Study to Evaluate Oral Formulations of Tedizolid Phosphate in Healthy Participants (MK-1986-043) (NCT06733688) | Merck Sharp & Dohme LLC | 2022-03-23 |
| A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment (NCT05241834) | Eli Lilly and Company | 2022-03-23 |
| A Brain Imaging PET Study of [11C]-Lu AF90103 in Healthy Adult Male Participants (NCT05306366) | H. Lundbeck A/S | 2022-03-23 |
| Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors (NCT05275478) | Tango Therapeutics, Inc. | 2022-03-23 |
| A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (NCT05295927) | Janssen Research & Development, LLC | 2022-03-23 |
| First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors (NCT05277051) | GlaxoSmithKline | 2022-03-22 |
| Study of OsrhAAT or Placebo in Healthy Volunteers (NCT05315921) | Healthgen Biotechnology Corp. | 2022-03-22 |
| Human Embryonic Stem Cell-Derived Cardiomyocyte Therapy for Chronic Ischemic Left Ventricular Dysfunction (NCT05068674) | Joseph C. Wu | 2022-03-22 |
| Inhaled Tobramycin in BPD (NCT04560179) | Erik Allen Jensen | 2022-03-22 |
| Accessorized Pre-Filled Syringe to Autoinjector Pharmacokinetic Bridging Study in Anifrolumab (NCT05339100) | AstraZeneca | 2022-03-22 |
| A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer (NCT05200364) | Sutro Biopharma, Inc. | 2022-03-22 |
| Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers (NCT05188469) | EyeGene Inc. | 2022-03-22 |
| Thal-Fabs: Reduced Toxicity Conditioning for High Risk Thalassemia (NCT05426252) | The Hospital for Sick Children | 2022-03-22 |
| Safety, Tolerability, and Pharmacokinetics of Naltrexone Implant (DLP-160) (NCT05304364) | Delpor, Inc. | 2022-03-22 |
| CD4^LVFOXP3 in Participants With IPEX (NCT05241444) | Bacchetta, Rosa, MD | 2022-03-22 |
| Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies (NCT05164458) | Innovent Biologics (Suzhou) Co. Ltd. | 2022-03-22 |
| A Phase 1 Trial to Evaluate CAP256V2LS in Healthy Adults (NCT04408963) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-03-22 |
| A Phase I/II Study of Recombinant Botulinum Toxin Type A for the Treatment of Moderate to Severe Glabellar Lines (NCT05743634) | Chongqing Claruvis Pharmaceutical Co., Ltd. | 2022-03-22 |
| BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors (NCT05010096) | M.D. Anderson Cancer Center | 2022-03-22 |
| Device-Less Technique in Islet Transplantation (NCT05073302) | University of Alberta | 2022-03-22 |
| PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies (NCT05107856) | Prelude Therapeutics | 2022-03-22 |
| The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers (NCT04781192) | University of Kansas Medical Center | 2022-03-22 |
| Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-1) (NCT05227846) | Beijing 302 Hospital | 2022-03-22 |
| A BCT Intervention for Physical Activity Among Individuals on Statins (NCT05273723) | Northwell Health | 2022-03-22 |
| Personalized DC Vaccines in Non Small Cell Lung Cancer (NCT05195619) | Centre Hospitalier Universitaire Vaudois | 2022-03-22 |
| Clinical Trial of TQB2825 in Subjects With CD20 Positive Hematological Tumors (NCT05489276) | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 2022-03-22 |
| Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors (NCT05262530) | BioNTech SE | 2022-03-22 |
| The Safety of Repurposing Daratumumab for Relapsed or Refractory Autoimmune Antibody Mediated Hemolytic Anemia (NCT05004259) | Dartmouth-Hitchcock Medical Center | 2022-03-21 |
| A Study in Healthy Volunteers to Compare the Pharmacokinetics of Sotorasib Administered as 1 or 2 Tablets (NCT05327491) | Amgen | 2022-03-21 |
| Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components (NCT05266404) | AstraZeneca | 2022-03-21 |
| Givinostat and Metabolites Pharmacokinetics in Urine and Plasma (Part 3) (NCT05860114) | Italfarmaco | 2022-03-21 |
| Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant (NCT04933968) | AlloVir | 2022-03-21 |
| The Potential of Givinostat as DDI Victim in Co-administration P-gp Inhibitor (Part 2) (NCT05845567) | Italfarmaco | 2022-03-21 |
| Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT (NCT05015426) | H. Lee Moffitt Cancer Center and Research Institute | 2022-03-21 |
| Perpetrator DDI Potential of Givinostat as Inhibitor and Inducer of CYP3A and P-gp Activity (NCT05492318) | Italfarmaco | 2022-03-21 |
| HFS (High-Fiber Supplement) in MS (Multiple Sclerosis) (NCT04574024) | Suhayl Dhib-Jalbut, MD | 2022-03-21 |
| A Study of DLX105-DMP in Subjects With Plaque Psoriasis (NCT04203433) | DelArrivo, Inc. | 2022-03-21 |
| AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in Pediatrics (NCT05281601) | AstraZeneca | 2022-03-21 |
| A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521 (NCT05323045) | Byondis B.V. | 2022-03-21 |
| Drug-drug Interactions Between DWP14012 and Aspirin in Healthy Subjects (NCT05304845) | Daewoong Pharmaceutical Co. LTD. | 2022-03-21 |
| Evaluating Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adults With Mild to Moderate COVID-19 (NCT05069610) | Advagene Biopharma Co. Ltd. | 2022-03-21 |
| Effects of Photobiomodulation in Children With Down Syndrome and Possible Sleep Bruxism (NCT04211870) | University of Nove de Julho | 2022-03-20 |
| The Effect of Dolutegravir on Whole-body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy Volunteers (NCT04771754) | Chelsea and Westminster NHS Foundation Trust | 2022-03-20 |
| The Safety, Tolerability, and Effectiveness of Quetiapine in Postpartum Depression (NCT04950868) | Verinder Sharma | 2022-03-18 |
| A Study in Healthy Men to Test Whether BI 425809 Influences the Amount of Midazolam in the Blood (NCT05258110) | Boehringer Ingelheim | 2022-03-18 |
| A Study Investigating Lu AG22515 in Healthy Adults (NCT05136053) | H. Lundbeck A/S | 2022-03-18 |
| Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Mild Hepatic Impairment Compared to Participants With Normal Hepatic Function (NCT05283915) | Sanofi | 2022-03-18 |
| A Study Investigating the Movement of Lu AG09222 Into, Through, and Out of the Body of Healthy Caucasian, Chinese, and Japanese Participants (NCT05304910) | H. Lundbeck A/S | 2022-03-18 |
| Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL (NCT05350787) | Zhejiang University | 2022-03-18 |
| A Study of Butamirate Citrate Syrup Versus (vs) Sinecod Syrup (Vanilla) in Adult Healthy Study Volunteers (NCT05182047) | McNeil AB | 2022-03-18 |
| Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (NCT05216835) | AstraZeneca | 2022-03-18 |
| Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With MRD+ B-ALL (NCT05350852) | Zhejiang University | 2022-03-18 |
| Evaluate the Safety and Effect of ThisCART19A in Patients With AIDS Related B Cell Lymphoma/Lympholeukemia (NCT05340829) | He Huang | 2022-03-18 |
| Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B-NHL After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy (NCT05349266) | Zhejiang University | 2022-03-18 |
| A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors (NCT05198752) | Stemirna Therapeutics | 2022-03-18 |
| A Clinical Study of AK115 in Healthy Subjects (NCT05286970) | Akeso | 2022-03-18 |
| Biosimilarity Study of Subcutaneous Pegfilgrastim in Healthy Volunteers (NCT04873765) | Megalabs | 2022-03-18 |
| A Single-Dose, Randomized, Open-Label, 2-Way Crossover Study to Evaluate the Dose-Proportionality, Safety, and Tolerability of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) in Healthy Japanese and Chinese Subjects (NCT07464535) | Tonix Pharmaceuticals, Inc. | 2022-03-18 |
| PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer (NCT05245006) | Robert Flavell, MD, PhD | 2022-03-18 |
| Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants (NCT05330858) | Alumis Inc | 2022-03-17 |
| A Study of LY3857210 in Healthy Participants (NCT05292040) | Eli Lilly and Company | 2022-03-17 |
| Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities (NCT05273320) | Hsiang-Yuan Lin | 2022-03-17 |
| Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML (NCT05275439) | Shattuck Labs, Inc. | 2022-03-17 |
| A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants (NCT05292131) | UCB Biopharma SRL | 2022-03-17 |
| A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia (NCT05219721) | Chunrui Li | 2022-03-17 |
| Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2 (NCT05321147) | Innate Pharma | 2022-03-17 |
| Radioligand fOr locAl raDiorecurrent proStaTe cancER (NCT05230251) | Glenn Bauman | 2022-03-17 |
| Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts (NCT04691622) | Children's National Research Institute | 2022-03-17 |
| A Study Evaluating the Safety, Tolerability, and Range of Biologically Active Doses of ICM-203 in Mild to Moderate Knee Osteoarthritis (NCT04875754) | ICM Biotech Australia Pty Ltd. | 2022-03-17 |
| PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation (NCT05120570) | Masonic Cancer Center, University of Minnesota | 2022-03-17 |
| Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia (NCT05157971) | City of Hope Medical Center | 2022-03-17 |